Introduction
The relationship between Mendelian disorders and their more common sporadic counterparts is a difficult problem especially highlighted by the adult onset neurodegenerative diseases. As both familial and sporadic disease overlap in either clinical syndrome or their characteristic pathology (or both) it can be argued that they share causative pathways. This is a critical assumption for developing molecular models of and, ultimately, treatments for the disease. There are, however, differences as well. Often, familial forms of these diseases are earlier in onset than their sporadic counterparts, have more aggressive course and have unusual clinical or pathological features. It has also been argued that sporadic diseases might simply be dissociated from genetic ones precisely because they do not have an obvious genetic component, so by definition they have different causes.
These arguments are particularly relevant to Parkinson's disease. To describe the terms used in this review, the diagnosis of Parkinson's disease is based on the strict presence and absence of a constellation of symptoms, validated post mortem by the two characteristic pathological changes of neuronal loss of dopaminergic cells in the substantia nigra and the presence of Lewy pathology [1] . Lewy bodies are intraneuronal inclusion bodies composed of many proteins including heavily aggregated forms of a small protein, a-synuclein [2] . The term parkinsonism is often used for the clinical syndrome driven by death of nigral neurons without neuropathological confirmation of Lewy bodies. There are now five genes unambiguously linked to Parkinson's disease or parkinsonism in multiple families, but whether they are instructive for idiopathic Parkinson's disease is debated. In this review, we will illustrate some of these concepts by discussing mutations in two genes found in 2004, both of which were described as causing 'Parkinson's disease' in their initial cloning papers, PINK1 and LRRK2. We will discuss specifically the evidence that relates these two observations to sporadic Parkinson's disease in the context of other known mutations causing similar phenotypes.
PINK1 and the difficulty of defining phenotypic categories for 'Parkinson's disease'
One argument against Parkinson's disease having a genetic cause (or causes) is that epidemiological studies have failed to see an effect of heritability on the lifetime risk for Parkinson's disease, especially where the age of onset was over 50 years. Heritability for early-onset Parkinson's disease (EOPD), however, is more easily demonstrated. The most recent gene for EOPD is PINK1 (from PTENinduced kinase 1) [3 ] . PINK1 encodes a mitochondrial kinase, linking genetic data with previous suggestions that mitochondrial dysfunction may be important in the pathogenesis of Parkinson's disease [4] . The mutations are almost certainly loss of function mutations. For example, we have shown that at least one mutation strongly destabilizes the protein whilst others may decrease kinase activity [5 ] . A more precise interpretation of the role of PINK1, neuronal survival, will remain uncertain until kinase substrates are identified.
A pressing concern for this review is that the neuropathology of PINK1 mutations is not known. By definition, if Lewy pathology is required for a diagnosis of Parkinson's disease, we do not know if PINK1 mutations lead to Parkinson's disease or parkinsonism, leading to an uncertain relationship to sporadic Parkinson's disease [6 ] . Association studies with single nucleotide polymorphisms spread across PINK1 gene have so far been negative [7 ,8 ] . Although this probably means that PINK1 plays a minor genetic role in sporadic Parkinson's disease, it is not proof that PINK1 has no relationship to pathogenesis in the more common disease. It is possible that there is only limited genetic variation at this locus within the population. The widespread findings of PINK1 mutations in apparently sporadic EOPD patients [9 ,10], however, clearly show that PINK1 mutations are an important cause of EOPD even in cases with negative family history. Therefore, PINK1 is definitively a gene for EOPD but until we better understand the pathology of these cases, and the molecular biology of the protein, we will not be able to answer the question of the relationship to sporadic Parkinson's disease.
Other genes responsible for recessive parkinsonism
To reiterate how difficult it can be to understand the relationship between recessive EOPD genes and sporadic Parkinson's disease it is worth briefly discussing recent studies of parkin and DJ-1. Mutations in the PRKN gene, coding for parkin, are relatively frequent among patients with EOPD, especially in cases with a positive family history [11 ,12] . Many cases with parkin mutations lack Lewy pathology, leading to the argument that parkin-associated disease is a distinct clinical entity from sporadic Parkinson's disease [13] . There are reports of parkin cases with distinct clinical phenotypes differing from sporadic Parkinson's disease [14 ,15 ] , supporting this argument. There have been reports of a wider spectrum of clinical pathological findings in parkin associated disease, however, blurring any rigid distinction between the two disease entities. Some cases have a-synuclein positive inclusion bodies, although these authors were careful not to call them 'Lewy bodies' [16 ] . What most commentators agree on is that the numbers of postmortem studies of the parkin brain are too small to make definitive conclusions. Although this might appear surprising given the frequency of mutations, the disease is milder than sporadic Parkinson's disease and hence patients with parkin mutations have longer survival times.
One of the most controversial issues in parkin disease is whether parkin mutations in a heterozygous state confer susceptibility to parkinsonism or even sporadic Parkinson's disease. Several recent studies [17, 18 ] showed that heterozygous parkin mutation carriers have reduced 18F-DOPA uptake upon positron emission tomography scanning, suggesting that possession of a single defective parkin allele causes a sub-clinical nigrostriatial dysfunction. By extension, this implies that parkin deficiency may contribute to late onset Parkinson's disease [19] . Although there were some initial suggestions that variation in the parkin gene may alter risk for sporadic Parkinson's disease [20] , however, some replication studies have been negative [21, 22] . Therefore, evidence suggesting that parkin plays a genetic role in sporadic Parkinson's disease is equivocal. Similarly, there is no strong evidence that genetic variation at the DJ-1 locus influences lifetime risk for sporadic Parkinson's disease, although such studies are more limited [23, 24 ,25] . Does this mean that recessive genes play no role in Parkinson's disease? At present there is no satisfactory answer: uncertainties about the pathology found in these cases and a lack of precision in understanding the cellular processes involved in cell death mean that we cannot unambiguously infer any specific pathways.
LRRK2 studies show that apparently sporadic disease can result from genetic lesions but also that pathology and gene can be dissociated. Second, one mutation, G2019S, is estimated to be responsible for 1% of typical sporadic cases and 5% of cases with family history (Fig. 1) Each pie chart is a single study, with the two slices representing the major and minor alleles; in each case the smaller areas are the mutation and the frequencies are labelled above each study. The North America, Europe and UK charts are for G2019S and Spain and Basque are for R1441C. The first five studies are all from familial or sibling-pair samples and thus are higher than the incidence in 'sporadic' Parkinson's disease.
widens the phenotype to a cortical disease. Interestingly, the recent 'Parkinson's disease' staging scheme proposed by Braak and co-workers follows a similar course with brainstem disease preceding cortical pathology [43 ,44] . If valid, this argument would imply that Parkinson's disease and DLBD are related causative entities [45] .
Can we use this information to understand the genetic determinants of sporadic Parkinson's disease? Numerous association studies have focused on a polymorphic repeat within the promoter region of SNCA (Rep1) [46,47 ,48 ], on the basis of the concept that elevated a-synuclein expression levels might affect disease risk. Not all studies, however, have been positive [49 ] . Part of the reason for this might be relatively technical; the Rep1 region is a complex, mixed repeat and it is not clear if different studies are talking about the same promoter variant. It is also important to realize that the 'dose' of a-synuclein required to have a detectable effect on the risk of Parkinson's disease might be quite small. The difference between the dramatic, dominantly inherited phenotype of the triplication cases and an unaffected person is only twofold, as we have confirmed by protein expression studies [50 ] . Smaller changes in expression might well be enough to increase risk but could be difficult to detect genetically.
The overall results tend towards an association with disease, supporting the hypothesis that the amount of a-synuclein is important in Parkinson's disease/DLBD in both its genetic and sporadic forms. Other recent data indicate that a-synuclein and its homologue b-synuclein are not essential for neuronal function and viability [51 ] , suggesting that targeting a-synuclein expression levels might be a useful target for future therapeutics. Therefore, of all the genes discussed, SNCA has the clearest link to non-inherited forms of Parkinson's disease, and probably has the greatest immediate utility in developing new ways to interrupt the pathogenic process.
Conclusion
It is reasonable to ask whether Mendelian diseases really can tell us much about a sporadic condition in which nongenetic causes are also likely to operate. An immediate test is to see if variants of the same genes contribute to the lifetime risk for sporadic disease in the population. This can be illustrated by the G2109S mutation in dardarin or the weaker association between a-synuclein and Parkinson's disease. We might stretch this conclusion a little and infer that genetics probably do contribute to common Parkinson's disease, but teasing out myriad small gene effects in the presence of what may be substantial non-genetic components will be a Herculean task. These current, and perhaps future, advances in genetics make the screening for various mutations possible, although the majority of gene-linked cases are still likely to have unusual features or early onset that might indicate differences from sporadic Parkinson's disease.
We may also expect the different genes to tell us about the process leading to disease, irrespective of whether they have genetic association with sporadic disease. In fact at a population level for a common disease, rare Mendelian variants may have negligible effects. Here we have to understand what the genes tell us, and this relies on precise phenotyping. At a crude level, and notwithstanding our uncertainties about the pathology of these cases, the recessive EOPD mutations are likely to tell us something about why specific sets of neurons can be lost to the disease process. Whether PINK1, DJ-1 and parkin converge in a common underlying pathway or whether they represent the end stage of parallel neurodegenerative disorders is not resolved. The dominant gene products tell us something about both inclusion body formation, manifesting generally as Lewy bodies, but also neuronal dysfunction. The link between a-synuclein and Parkinson's disease is obvious and direct, whereas uncovering the link between dardarin and sporadic disease will require substantial further investigative effort.
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